Hepatotoxins

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

Global Paracetamol Market Demand 2020-2024: Growing Use of Paracetamol as an Antipyretic for COVID-19 Drives Market Growth - ResearchAndMarkets.com

Thursday, May 21, 2020 - 11:46am

The paracetamol market is poised to grow by $ 484.77 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period.

Key Points: 
  • The paracetamol market is poised to grow by $ 484.77 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period.
  • This report on the paracetamol market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study also identifies the growing number of approvals for paracetamol-based combinations as another key reason driving the paracetamol market growth during the next few years.
  • The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Hormone Replacement Therapy Market Size Worth $39.6 Billion By 2027: Grand View Research, Inc.

Tuesday, May 19, 2020 - 9:05am

The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.

Key Points: 
  • The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.
  • Key suggestions from the report:
    The estrogen replacement therapy segment dominated the overall market in terms of revenue share in the year 2019.
  • About 73% of postmenopausal women suffer from hot flashes
    North America dominated the overall hormone replacement therapy market in terms of revenue share in the year 2019.
  • Grand View Research has segmented the global hormone replacement therapy market based on product, route of administration, type of disease, and region:
    Hormone Replacement Therapy Product Outlook (Revenue, USD Million, 2016 - 2027)
    Hormone Replacement Therapy Route of Administration Outlook (Revenue, USD Million, 2016 - 2027)

Hormone Replacement Therapy Market Size Worth $39.6 Billion By 2027: Grand View Research, Inc.

Tuesday, May 19, 2020 - 9:05am

The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.

Key Points: 
  • The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.
  • Key suggestions from the report:
    The estrogen replacement therapy segment dominated the overall market in terms of revenue share in the year 2019.
  • About 73% of postmenopausal women suffer from hot flashes
    North America dominated the overall hormone replacement therapy market in terms of revenue share in the year 2019.
  • Grand View Research has segmented the global hormone replacement therapy market based on product, route of administration, type of disease, and region:
    Hormone Replacement Therapy Product Outlook (Revenue, USD Million, 2016 - 2027)
    Hormone Replacement Therapy Route of Administration Outlook (Revenue, USD Million, 2016 - 2027)

Cory Watson Attorney Lauren S. Miller Appointed to Plaintiffs' Steering Committee in Zantac Litigation

Monday, May 18, 2020 - 7:00pm

BIRMINGHAM, Ala., May 18, 2020 /PRNewswire-PRWeb/ --Cory Watson attorney Lauren S. Miller has been named to the Plaintiffs' Steering Committee (PSC) for In Re: Zantac (Ranitidine) Products Liability Litigation, the multidistrict litigation involving Zantac medication linked to cancer.

Key Points: 
  • BIRMINGHAM, Ala., May 18, 2020 /PRNewswire-PRWeb/ --Cory Watson attorney Lauren S. Miller has been named to the Plaintiffs' Steering Committee (PSC) for In Re: Zantac (Ranitidine) Products Liability Litigation, the multidistrict litigation involving Zantac medication linked to cancer.
  • Ms. Miller is one of 20 attorneys appointed by U.S. District Judge Robin L. Rosenberg to the PSC out of 62 applicants.
  • "I'm honored to be selected to work with this incredibly talented group of attorneys to lead this nationwide litigation," said Ms. Miller.
  • Lauren S. Miller joined Cory Watson Attorneys in 2015 and is licensed to practice law in the state and federal courts of Alabama.

Roopal Luhana Appointed to Plaintiffs' Steering Committee for Zantac MDL

Monday, May 18, 2020 - 3:00pm

NEW YORK, May 18, 2020 /PRNewswire-PRWeb/ -- Chaffin Luhana LLP , a national plaintiffs-only law firm, is pleased to announce that Founding Partner Roopal P. Luhana was recently appointed by U.S. District Judge Robin L. Rosenberg to the Plaintiffs' Steering Committee (PSC) in the In re: Zantac (Ranitidine) Products Liability Litigation (S.D.FL.

Key Points: 
  • NEW YORK, May 18, 2020 /PRNewswire-PRWeb/ -- Chaffin Luhana LLP , a national plaintiffs-only law firm, is pleased to announce that Founding Partner Roopal P. Luhana was recently appointed by U.S. District Judge Robin L. Rosenberg to the Plaintiffs' Steering Committee (PSC) in the In re: Zantac (Ranitidine) Products Liability Litigation (S.D.FL.
  • Luhana was also named Chair of the ESI/Document Production Committee.
  • The Zantac MDL was established by the U.S.
  • "I'm honored that Judge Rosenberg appointed and entrusted me to assist in steering this litigation.

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

Monday, May 18, 2020 - 11:00am

Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.

Key Points: 
  • Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

Analysis on Impact of COVID19-Global Paracetamol Market 2020-2024 | Evolving Opportunities with Anhui BBCA Likang Pharmaceutical Co. Ltd. and Anqiu Luan Pharmaceutical Co. Ltd. | Technavio

Friday, May 15, 2020 - 7:30pm

Despite the impact of the COVID-19 pandemic, market growth is expected to decelerate at a CAGR of about 8%.

Key Points: 
  • Despite the impact of the COVID-19 pandemic, market growth is expected to decelerate at a CAGR of about 8%.
  • In addition, the growing number of approvals for paracetamol-based combinations is anticipated to boost the growth of the paracetamol market.
  • Anhui BBCA Likang Pharmaceutical Co. Ltd.
    Anhui BBCA Likang Pharmaceutical Co. Ltd. offers paracetamol as an API in various solid and liquid formulations, paracetamol tablets, and Cefuroxime Axetil in bulk quantities.
  • These raw materials largely consist of paracetamol, paracetamol DC (fluid bed), paracetamol DC (spraying dry), P-Aminophenol, Sodium Acetate, white emulsion, etc.

Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Friday, May 15, 2020 - 1:30pm

The Algernon team is working hard to finalize the U.S. FDA IND application and will be updating the market on its progress shortly.

Key Points: 
  • The Algernon team is working hard to finalize the U.S. FDA IND application and will be updating the market on its progress shortly.
  • The data will determine the number of expected patients needed to reach statistical significance in the Phase 3 trial.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
  • Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

Technological Advances in the Anti-Viral Drug Therapy Market to Aid Treatment of COVID-19 Patients, Reports TBRC

Thursday, May 14, 2020 - 4:30pm

Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.

Key Points: 
  • Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.
  • The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of the anti-viral drugs market.
  • Increasing public-private funding for life science research globally is also expected to drive the growth of the global anti-viral drug therapy market.
  • Request A Free Sample Of The Anti-Viral Drug Therapy Market Report:
    The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.